Nuwellis Touts Data Supporting Lower Heart Failure Hospitalizations & Readmissions With Aquadex

Nuwellis Inc NUWE announced the peer-reviewed publication of the results from a 10-year, real-world retrospective analysis in patients using the Aquadex FlexFlow System.
The study included 334 hospitalized acute decompensated heart failure patients with fluid overload.
The analysis demonstrated significant reductions in heart failure hospitalizations and 30-day hospital readmission rates, and improvements in renal function response using Aquadex ultrafiltration.
The published study findings included: Patients experienced an overall 81% decrease in heart failure hospitalizations per year;
Rehospitalizations for patients after receiving UF with Aquadex were 48% less than the national average at 30 days (12.4% vs. 24%);
55% of patients achieved sustained weight loss greater than 15 lbs.; and
All patients had a stable renal function at follow-up.
Price Action: NUWE shares are up 20.18% at $13.52 on the last check Tuesday.